Mentioned Users

myRAteam

Erelzi (Etanercept-szzs) is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat rheumatoid arthritis. It is a biosimilar of Enbrel and works by attaching to tumor necrosis factor alpha (TNF-α), preventing it from signaling the immune system to attack the connective tissues. Erelzi is Show Full Answer

Erelzi (Etanercept-szzs) is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat rheumatoid arthritis. It is a biosimilar of Enbrel and works by attaching to tumor necrosis factor alpha (TNF-α), preventing it from signaling the immune system to attack the connective tissues. Erelzi is administered as a subcutaneous injection once a week and is available as a single-use, prefilled syringe or pen.

Common side effects include:
- Infections
- Injection site reactions

Rare but serious side effects include:
- Severe infections
- Nerve disorders (e.g., multiple sclerosis, Guillain-Barré syndrome)
- Heart failure
- Low blood cell counts
- Hepatitis B virus reactivation
- Severe allergic reactions
- Increased risk for lymphoma and other cancers

For more details, you can visit:
- [Erelzi — RxList](https://www.rxlist.com/erelzi-drug.htm)
- [Erelzi — RheumInfo](https://rheuminfo.com/medications/erelzi/)

 This AI-generated response comes from myRAteam and other selected sources. It is not a substitute for medical advice. Always ask your doctor about specific health concerns.

Erelzi (Etanercept-szzs) for Rheumatoid Arthritis | myRAteam

Enbrel Biosimilar Works Well, Yet Some Patients Still Prefer the Originator Drug